Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 497

Results For "UP"

7718 News Found

Piramal Pharma starts production at new API facility in Riverview, Michigan
News | February 20, 2023

Piramal Pharma starts production at new API facility in Riverview, Michigan

New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)


Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions
Digitisation | February 20, 2023

Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions

Agasta Software is engaged in research, development and commercialization of medical devices


Briefs: Neuland Laboratories, Cipla and Zydus
Drug Approval | February 20, 2023

Briefs: Neuland Laboratories, Cipla and Zydus

Cipla has received 8 inspectional observations in Form 483


Zydus receives tentative approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets
Drug Approval | February 20, 2023

Zydus receives tentative approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States


India achieves 15,000+ transplants in a year
News | February 20, 2023

India achieves 15,000+ transplants in a year

There is a fast resurgence in the transplant activities post COVID


Fluor selected by Agilent for expansion of oligonucleotide manufacturing facility in Colorado
News | February 19, 2023

Fluor selected by Agilent for expansion of oligonucleotide manufacturing facility in Colorado

Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability


USFDA accepts for priority review the sNDA for Merck’s Prevymis
Drug Approval | February 18, 2023

USFDA accepts for priority review the sNDA for Merck’s Prevymis

FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients


IAGES collaborates with technology leaders in robotic surgery
News | February 18, 2023

IAGES collaborates with technology leaders in robotic surgery

IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023


Merck and AstraZeneca present final results from Phase 3 PROpel Trial
Drug Approval | February 18, 2023

Merck and AstraZeneca present final results from Phase 3 PROpel Trial

Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival


Pfizer announces Talzenna and Xtandi combination data from phase 3 study
News | February 18, 2023

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI